ROPN1: A Promising Drug Target / Biomarker (G54763)

Target Name: ROPN1

NCBI ID: G54763

ROPN1

ROPN1: A Promising Drug Target / Biomarker

ROPN1 (Ribonucleotide-Oriented Programming of Neurogenesis), also known as P24, is a non-coding RNA molecule that plays a crucial role in the development and maintenance of neural stem cells (NSCs) in the brain. It is a key regulator of the neural stem cell proliferation and differentiation, and is involved in the formation of various neural tissues, including the brain. ROPN1 is also a drug target of interest, and has been identified as a potential therapeutic target for various neurological and psychiatric disorders.

Structure and Function
ROPN1 is a small non-coding RNA molecule that consists of 194 amino acid residues. It is expressed in a variety of tissues and cells, including neural stem cells, brain neurons, and glial cells. ROPN1 is primarily localized to the cytoplasm of these cells, and is involved in the regulation of gene expression.

ROPN1 functions as a negative regulator of the transcription factor, PDXR. PDXR is a key regulator of neuronal differentiation and is involved in the formation of various neural tissues. ROPN1 binds to the PDXR protein and prevents it from activating target genes. This inhibition of PDXR function renders it a potential drug target for the treatment of neurological and psychiatric disorders.

ROPN1 is also involved in the regulation of cellular processes such as cell adhesion, migration and invasion. It has been shown to play a role in the regulation of neural cell-cell adhesion, and is involved in the development of neural tissues.

Expression and Disease
ROPN1 is expressed in a variety of tissues and cells, including neural stem cells, brain neurons, and glial cells. It is shown to be involved in the development and maintenance of neural stem cells, and is considered a potential therapeutic target for the treatment of neurological and psychiatric disorders.

ROPN1 has been shown to be involved in the development of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Studies have shown that individuals with certain genetic variations in the ROPN1 gene are at increased risk for the development of these disorders.

In addition, ROPN1 has also been shown to be involved in the regulation of pain perception and neuroinflammation. It has been shown to play a role in the regulation of pain sensitivity and the response to pain modalities, and is also involved in the regulation of neuroinflammation.

Drug Target
ROPN1 is a potential drug target for the treatment of neurological and psychiatric disorders. Studies have shown that ROPN1 is involved in the development and maintenance of neural stem cells, and is a key regulator of the neural stem cell proliferation and differentiation.

In addition, ROPN1 is also involved in the regulation of cellular processes such as cell adhesion, migration and invasion, and is a potential therapeutic target for the treatment of various neurological disorders.

Conclusion
ROPN1 is a non-coding RNA molecule that plays a crucial role in the development and maintenance of neural stem cells in the brain. It is a key regulator of the neural stem cell proliferation and differentiation, and is involved in the formation of various neural tissues. ROPN1 is also a potential drug target for the treatment of neurological and psychiatric disorders. Further research is needed to fully understand the role of ROPN1 in neural development and disease.

Protein Name: Rhophilin Associated Tail Protein 1

Functions: Important for male fertility. With ROPN1L, involved in fibrous sheath integrity and sperm motility, plays a role in PKA-dependent signaling processes required for spermatozoa capacitation

The "ROPN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ROPN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets